Background. Fluoroscopic-guided placement of a percutaneous decompression gastrostomy tube (PDGT) is used to palliate patients with malignant bowel obstruction (MBO). We report our clinical experience in cases of MBO and ascites that were known to be technically difficult and at increased risk for complications after PDGT placement. Methods. Between October 2005 and April 2010, a total of 89 consecutive oncology patients with MBO and ascites underwent at least one attempt at PDGT placement. We retrospectively reviewed the electronic medical record to collect demographic details, procedure information, and morbidity and mortality data. Kaplan-Meier curves were used to calculate median survival after PDGT. Results. Ninety-three new gastrostomy encounters occurred in 89 patients. The primary and secondary technical success rates were 72 % (67 of 93) and 77.4 % (72 of 93), respectively. Inadequate gastric distention was the reason for failure in 84.6 % (22 of 26) of the cases in which the initial PDGT attempt was unsuccessful. For ascites management, 13 patients underwent paracentesis and 78 patients underwent placement of an intraperitoneal catheter. The overall complication rate in successful placements was 13.9 %, with a major complication rate of 9.7 %. After PDGT, the median overall survival rate was 28.5 days (95 % confidence interval 20-42). Conclusions. PDGT is feasible in the majority of patients with MBO and ascites, although there is an inherent risk of major complications. An intraperitoneal catheter can be used to manage ascites to facilitate PDGT.
Malignant bowel obstruction (MBO) is a common manifestation in terminal cancer patients, occurring in up to 42 % of patients with advanced ovarian cancer and up to 24 % of patients with advanced colorectal carcinoma. [1] [2] [3] [4] [5] [6] Given that the surgical management of MBO has been associated with 30-day mortality rates of up to 40 %, venting gastrostomy, placed either endoscopically (PEG) or fluoroscopically, has been advocated for the palliation of these patients. 2, 4, [7] [8] [9] [10] A venting gastrostomy obviates the need for nasogastric suction, and, together with intravenous hydration and pharmacologic support, it allows for terminally ill patients to be cared for at home or in hospice. 11 Although the etiology of bowel obstruction in patients with advanced cancer is multifactorial (malignant vs. benign, mechanical vs. functional), MBO, brought on by mechanical compression of bowel loops or impairment of bowel peristalsis, is a frequent manifestation of patients with extensive peritoneal carcinomatosis. [12] [13] [14] [15] [16] [17] The presence of peritoneal disease, and often coexisting ascites, can make fluoroscopic-guided percutaneous decompression gastrostomy tube (PDGT) placement technically challenging, and are considered by some to be a contraindication to endoscopic or PDGT placement. [18] [19] [20] [21] [22] Peritoneal tumor implants can limit access to and prevent adequate distention of the stomach. 23 Peritoneal carcinomatosis is also the most common cause of malignant ascites, which by itself is also an independent factor that can complicate the management of MBO. [24] [25] [26] Ascites is considered a relative contraindication to percutaneous gastrostomy for the following reasons: the fluid can make puncturing the anterior wall of the stomach more difficult; the development of ascites between the stomach and the abdominal wall can increase the intraperitoneal catheter length and may predispose to tube dislodgment; and finally, ascites may prevent maturation of a tube track, thus facilitating pericatheter leakage of ascites and/or gastric contents, which may result in skin breakdown and/or peritonitis. 19, 21, 22, 27 The potential pitfalls associated with PDGT placement in the presence of peritoneal carcinomatosis and ascites render the palliation of terminal cancer patients with MBO and ascites challenging. A meta-analysis of the gastrostomy literature by Wollman et al. did not consider this subset of patients separately when reporting complications and outcomes. 28 As a result, the risks and outcomes of PDGT in this high-risk patient population are poorly understood. The aim of this study was to assess the feasibility and safety of PDGT placement in terminal cancer patients with MBO and concomitant ascites.
MATERIALS AND METHODS
This study was approved by the institutional review board, and a waiver of informed consent was obtained for this retrospective, Health Insurance Portability and Accountability Act-compliant review. The electronic medical records of all patients with MBO and concomitant ascites (n = 89) who were referred to interventional radiology for PDGT from October 2005 to April 2010 were reviewed.
All patients had advanced malignancy (Table 1) , intestinal obstruction, and coexisting ascites (20 male and 69 female patients; age range, 22-83 years; median age of 57 years). In three patients, PDGT placement was required on more than one distinct occasion, separated by more than 6 months from initial PDGT removal to reinsertion. For the purposes of this study, all PDGT attempts that occurred more than 6 months apart were considered new encounters, and thus 93 new PDGT encounters were used to calculate primary technical success. Repeat catheter insertion attempts within 7 days of each new encounter were used to determine secondary technical success.
All patient records and imaging studies were reviewed. Data elements collected included demographic information, procedure technique, fluid management method, complications, and overall survival. Preprocedural diagnostic cross-sectional imaging and relevant endoscopy reports were reviewed by an interventional radiologist (A.T.) to document the presence of gastric wall involvement and the presence of peritoneal carcinomatosis, and to subjectively classify the volume of ascites.
All procedures were performed, under monitored moderate sedation or sedation provided by the anesthesiology service, by an interventional radiologist after written informed consent was obtained. Patients underwent a minimum of overnight nasogastric tube (NGT) decompression of the stomach before the procedure. Ascites was managed by paracentesis or placement of a 10F nontunneled intraperitoneal (i.p.) drain (Mac-Loc catheter; Cook Medical, Bloomington, IN), performed in the days before or at the time of PDGT placement. After adequate drainage of the ascites, as assessed by ultrasound, a PDGT was placed via fluoroscopic guidance and Seldinger technique. 29 Typically, a 14F catheter with a self-locking retention loop (Mac-Loc catheter; Cook Medical) was placed for gastric decompression. The PDGT was connected to gravity drainage, and after 24 h, the NGT was removed and diet advanced. Caregivers were educated on how to care for the PDGT and i.p. catheter. Up to 1 L of fluid was to be drained from the i.p. catheter daily, and the tube capped in the interim. If symptom relief was inadequate, the caregiver was advised to contact the interventional radiology service to discuss the concerns, and the volume drained could be adjusted if appropriate. No routine additional follow-up was performed to evaluate for the presence of residual ascites. The PDGT was to be connected to gravity drainage. Patients who were able to eat were advised to cap the tube during and for 1 h after meals. Dressings were to be changed daily. For each patient, the end of follow-up was defined as the date of death or date of last contact. The Kaplan-Meier method was used to estimate the distribution of the times to discharge and death after PDGT insertion, and distributions were compared by the log-rank test. One patient had three separate successful tube placements on separate dates; this patient was considered three times for the analysis of time to discharge, but only once in survival analyses. Complications were classified by outcome according to the Society of Interventional Radiology guidelines and the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. 30, 31 The impact of technical factors on the development of a complication was evaluated by Fisher's exact tests and Student t-tests. All statistical analyses were performed by SAS 9.2 for Windows (SAS, Cary, NC), and a p value of \ 0.05 was considered statistically significant.
RESULTS
The primary and secondary technical success rates for PDGT placement were 72 % (67 of 93) and 77.4 % (72 of 93), respectively. Table 2 summarizes the imaging findings and procedural details for the patient group. The median interval between drainage of ascites and attempted PDGT placement in successful placements was 1 day (range 0-79 days) with 29 patients receiving their paracentesis or i.p. catheter immediately preceding the PDGT placement attempt.
The failure rate of PDGT placement on new encounters was 28 % (26 of 93), of which 39 % (10 of 26) and 23 % (6 of 26) occurred in patients with ovarian and gastric primary disease, respectively. Secondary attempts were performed within 7 days of the initial PDGT encounter in 27 % (7 of 26) and was ultimately successfully in 5 out of 7 patients. Inadequate gastric distention was the primary reason for failure to place a PDGT in 84.6 % (22 of 26). Supportive measures such as the use of anesthesia for deep sedation, the use of C-arm cone beam computed tomography to delineate a percutaneous access route, and the use of a long micropuncture needle were used to overcome this technical challenge during five of the seven secondary attempts at PDGT placement (71.4 %). A large volume of residual ascites prevented placement of a PDGT in only one patient despite the presence of an i.p. catheter. For the 26 patients whose initial attempt at PDGT placement failed, the final management of MBO was as follows: successful placement of a PDGT either via a percutaneous or endoscopic route (n = 8), placement of a decompression duodenostomy (n = 1), placement of a tube for bowel decompression through an existing enterocutaneous fistula (n = 1), NGT drainage (n = 8), nothing (n = 3), and disposition not available (n = 5).
Follow-up was available for the 70 patients who underwent successful placement of a PDGT. The overall complication rate was 13.9 % (10 of 72), with a 9.7 % (n = 7) major (more than grade 3) and a 4.2 % (n = 3) minor (grade 1 or 2) complication rate ( Table 3) . The overall pericatheter leakage rate was 6.9 % (5 of 72), with pericatheter leakage of gastric contents and ascites occurring in 50 % of patients with complications. Four patients, all with peri-PDGT leakage, developed peritonitis with isolation of an organism. Ninety-six percent (75 of 78) of patients who underwent i.p. catheter placement for ascites management did not develop peritonitis. There were no cases of peritonitis in the 13 patients who underwent paracentesis or the two patients in whom no intervention was required.
Three of the patients with major complications had clinic notes in the medical record documenting improper care or usage of the i.p. catheter or PDGT, such as prolonged clamping of one or both tubes, infrequent drainage of ascitic fluid, or failure to change the dressings around the catheters. There was no evidence of an association CBCT C-arm cone beam computed tomography, PDGT percutaneous decompression gastrostomy tube a A T-fastener is a tool used for gastropexy where the stomach is fixed to the anterior abdominal wall b CBCT is an advanced 3-D imaging tool available in the interventional radiology suite. It allows for the acquisition and reconstruction of multiplanar, computed tomography-like images during fluoroscopic-guided interventions between the development of a complication and age (P = 0.22), gender (P = 0.68), type of malignancy (P = 0.76), the use of a T-fastener for gastropexy (P = 0.50), the use of an i.p. catheter (P = 0.67), or time interval between ascites drainage and PDGT placement (P = 0.98), although it should be noted that the number of complications was small.
Patients were discharged at a median of 2 days (range 0-60 days, 95 % confidence interval 2-3) after PDGT placement. The log-rank test showed a trend toward statistical significance (P = 0.053) when comparing the time to discharge after placements with complications (n = 10, median 7 days) and placements without complications (n = 62, median 2 days) (Fig. 1) . Most complications (70 %) manifested after discharge. The longest time to a complication occurred 90 days after PDGT placement in a patient who developed an enterocutaneous fistula. The tube had traversed the small bowel, and the patient became symptomatic only after the PDGT was removed. Fifty-one patients were discharged home, 26 of whom received home hospice services. Of the remaining patients, 16 were discharged to an inpatient hospice facility and two to longterm acute care facilities, and three died in the hospital at 1, 14, and 44 days after PDGT placement. Mortality data were available for 95.7 % (67 of 70) of patients who underwent successful PDGT placement. The median overall survival time was 28.5 days (range \24 h to 620 days, 95 % confidence interval 20-42) (Fig. 1) .
DISCUSSION
MBO is often a preterminal event in patients with advanced malignancy. The average survival rate for patients treated medically after the onset of MBO has been reported to be between 13.4 days and 3.7 months. 32 The symptoms of MBO make the condition debilitating, and palliation, while clinically challenging, is clearly necessary for these patients at the end of life. The palliative care literature has demonstrated PEG or PDGT placement resolves nausea and vomiting symptoms in 84-100 % of patients; permits diet advancement; and, in some patients, facilitates the continuation of palliative chemotherapy. [33] [34] [35] [36] [37] [38] Although PDGT has largely replaced surgery and is a better alternative to long-term NGT placement for the relief of obstructive symptoms in patients with MBO and ascites, there is a gap in knowledge as to the true risk for this procedure in this high-risk patient population. This study demonstrated that PDGT placement was feasible in 77 % of patients. Furthermore, we noted that i.p. catheter drainage was successful in alleviating ascites and facilitating PDGT placement without increasing the risk of infection. Table 4 reviews and summarizes the literature on PEG or PDGT placement in patients with MBO. Most studies are retrospective in nature, with small patient numbers and no consistent reporting of a method for ascites management. The reported failure rates range 0-11 %, as compared to our rate of 23 %. Most of the studies in the literature review were published over 10 years ago, and the higher rate of failure in this study may be related to changes that have occurred in the patient population over time. Given the advances in oncologic therapy, the patients we are seeing now have been through more surgical and medical treatments, which may make their disease more advanced at presentation for PDGT placement. We are also deliberately selecting patients with ascites, a known factor complicating technical success, which contributes to selection bias. Lastly, our experience may simply reflect a greater willingness to make an initial attempt at PDGT placement despite preprocedure imaging findings suggestive of technical failure.
Patients with ovarian or gastric carcinoma were the most technically challenging for PDGT placement, accounting for 62 % of initial placement attempt failures in this study. This may be the result of undiagnosed tumor infiltration of the stomach, which is frequently underestimated on standard imaging and a hindrance to gastric distention, which was the major reason listed for technical failure. Repeat attempts at PDGT placement with additional supportive measures, such as the use of anesthesia services and advanced imaging technology (i.e., C-arm cone beam computed tomography), may be required to adequately drain these patients if an initial attempt at placement fails.
The second major finding of this study is that i.p. catheters can be used to manage ascites in patients with MBO in preparation for and after placement of PDGT. Our use of i.p. catheters, as opposed to repeat paracenteses for the management of fluid reaccumulation, has not been associated with an increased risk of infection, as previously hypothesized. 19 Ninety-six percent of our patients who were treated with i.p. catheter placement had no evidence of peritonitis during follow-up. Considering the short median survival of these patients, a single i.p. catheter allows for periodic and continued drainage of the ascitic fluid and eliminates the burden of having to return to the hospital for repeat sonography and/or paracentesis at the end of life. 23 Although ascites does not preclude placement of PDGT, its presence or reaccumulation is a risk for morbidity. 18, 19, 22 Peri-PDGT leakage of ascitic fluid or gastric contents is not uncommon and has been reported to range 10-27 % (Table 4 ). In our series, ascites was a contributing factor in five of seven major complications. This underscores the importance of optimizing the drainage of the ascitic fluid and the need for proper education on   FIG. 1 a Kaplan-Meier survival curve demonstrating the probability of survival after PDGT placement (n = 70). The median overall survival time after PDGT insertion was 28.5 days. b Kaplan-Meier curve for time to discharge after PDGT insertion stratified by complication status in days (n = 72), P = 0.053 catheter maintenance. The ability of the patient or family to manage and maintain the PDGT and i.p. catheter appropriately is critical to mitigating periprocedural morbidity. The limitations of this study include bias inherent in a retrospective review. There was a lack of standardization among the operators with respect to PDGT placement technique, thus impeding the interpretation of how these variables potentially affect patient outcomes. Furthermore, it was difficult to assess these patients for symptom resolution, as this was not consistently documented in the medical record and many patients were discharged to hospice without subsequent follow-up. The number of complications (n = 10) was too few to use regression models to predict complication status. Despite these limitations, the study represents a detailed look at the potential for complications after PDGT in this high-risk group of patients.
Our major complication rate of 9.7 % is greater than that reported by Bell et al. 28,29 PDGT remains the best option for long-term palliation of symptoms related to MBO, and for most patients, it is a safe and effective procedure; however, it is essential that the increase in risk for major complications be acknowledged and discussed with the patient during the consent process. A multidisciplinary approach to the management of a patient with MBO both facilitates and optimizes the medical, surgical, and minimally invasive treatment options for symptom palliation and preservation of quality of life. 38, 39 As a result of this study, we have adopted an algorithmic and staged approach (Fig. 2) , similar to that of Laval et al., to the evaluation of a patient who may require a PDGT. 37 The first step for patients who have MBO and ascites that have not responded to medical management and who are not eligible for surgical management is to undergo i.p. catheter placement. If the i.p. catheter fails to relieve symptoms, patients undergo a trial of NGT decompression. Because symptom relief from NGT decompression is predictive of clinical success from PDGT, only patients whose symptoms are alleviated by NGT decompression are accepted for PDGT placement. 35 In conclusion, patients with MBO and ascites represent a unique subgroup of patients requiring gastrostomy placement. These patients have disease characteristics that make them technically challenging cases and that also inherently increase their risk for major complications. 
